Chinese demand for medicines helps Astrazeneca return to growth February 14, 2019 Strong growth in Chinese demand for new medicines helped Astrazeneca return to growth in 2018, it said today. The figures Product sales grew four per cent in 2018 compared to 2017, to hit $21bn (£16.35bn) in revenue. Fourth quarter revenue grew to $5.77bn, up five per cent year on year. Read more: Bristol-Myers Squibb to [...]
Trade body says hardcore of ‘repeat offenders’ are failing to listen to investor views December 4, 2018 The trade body for UK investment managers has written to 32 companies on the Ftse-all share to register concern after they faced significant shareholder dissent for the last two years. The Investment Association (IA) said it was concerned that these companies had appeared on the public register, which tracks significant shareholder dissent, for the same [...]
FTSE 100 roundup: Today’s winners and losers November 16, 2018 The FTSE 100 lost ground today, down 5.31 points at 7,032.70 just before markets closed after a turbulent start to the day when it lost as much as 0.8 per cent. All week markets have been reacting to the political fallout from Brexit as the FTSE 100 wiped out gains made late last week. Top 5 FTSE [...]
Astrazeneca shows disappointing results in trial of key cancer drug, shares dip November 16, 2018 Shares in Astrazeneca dipped after the pharmaceutical giant revealed it had not reached the results it had hoped for from a trial of a key drug. Patients treated with the drug Imfinzi on its own and combined with the tremelimumab antibody were not significantly more likely to survive than those treated with chemotherapy alone, researchers found. [...]
Theresa May’s new merger powers would be a hostile takeover by the state October 16, 2018 Back in July 2016, Theresa May launched her campaign for leadership of the Conservative party by promising radical action on foreign takeovers of British businesses. In the wake of Kraft’s takeover of Cadbury and Pfizer’s failed bid for AstraZeneca, May promised to defend workers and local communities from transient shareholders who, she said, were more [...]
AstraZeneca wins approval for major heart attack drug Brilinta in the US September 4, 2015 AstraZeneca has won approval for the sale of a potential blockbuster drug in the US. Brilinta, which thins the blood of former heart attack victims, won approval from the Food and Drug Administration last night, and is expected to be made available in pharmacies from the end of September. Read more: AstraZeneca sells drug [...]
Here’s what we can learn from the 10 biggest deals in pharmaceutical history August 7, 2015 The pharmaceutical world is abuzz about a major deal struck between AbbVie and small biotech company Pharmacyclics last night. The US pharma giant bought Pharmacyclics for a massive $21bn (£13.8bn), after fending off fierce competition from the likes of Johnson & Johnson. Why? To get its hands on the firm's super-successful cancer drug Imbuvrica, whose [...]
Astrazeneca’s revenue better than forecast July 30, 2015 ASTRAZENECA revenue fell by a smaller-than-expected seven per cent in the second quarter, as income from selling rights to medicines offset generic competition to older drugs and a strong dollar. The drugmaker increased its revenue forecast for the year and said it now expected a low single-digit percentage decline, against mid single-digit previously, while core [...]
AstraZeneca sells drug for $215m to Tillotts as it focuses on core products July 9, 2015 AstraZeneca has sold a gastrointestinal drug to Tillotts Pharma, a Swiss based pharmaceutical company, for $215m (£140m) as it slims down to focus on cancer and other core products. The British-Swedish multinational has disposed of all non-US rights for Entocort, a treatment for Crohn’s disease and ulcerative colitis, in the most recent of a string [...]
AstraZeneca chief executive questions UK’s commitment to treating cancer June 3, 2015 AstraZeneca chief executive Pascal Soriot has warned that the UK is lagging behind in cancer care innovation, after the government's drugs approval body rejected a new ovarian cancer drug already used in France and Germany as being too expensive. Read more: Why only Scottish patients are getting the best new drugs on the NHS “How can [...]